In a former decision impact study, our group was able to demonstrate that using EPclin as a risk stratification tool in routine clinical practice results in substantial avoidance of adjuvant CTX in endocrine-sensitive, HER2-negative breast cancer [14]. The gene discussed is ERBB2; the disease is breast carcinoma.